June 15-18, San Francisco, Calif., Moscone CenterBreaking news on sexual performance, diabetes, combating obesity, steroid abuse and growth hormone doping will be presented in a series of news briefings at ENDO 08, the 90th annual meeting of The Endocrine Society.Sunday, June 15Sexy Sex Findings (8:30 a.m. PDT): Breaking news on sexual performance for men and women.

UroToday.com - The prevalence of hypospadias varies widely among different countries and populations, ranging from 0.37-41 per infants1 and the prevalence in Hokkaido, Japan is 3.9 per 10,000 infants2. The etiology of hypospadias is still unclear, but it is regarded as a complex disorder with both genetic and environmental contributions.

A tiny modification called methylation on estrogen receptors prolongs the life of these growth-driving molecules in breast cancer cells, according to research by scientists at Emory University's Winship Cancer Institute.The results are published in the May 9, 2008 issue of the journal Molecular Cell.Most breast cancers contain estrogen receptors, which enable them to grow in the presence of the hormone estrogen.

Medical College of Wisconsin researchers in Milwaukee have shown for the first time that thrombopoietin (TPO), a naturally occurring protein being developed as a pharmaceutical to increase platelet count in cancer patients during chemotherapy, can also protect the heart against injury during a heart attack.The study, led by John E.

Genzyme Corp. (Nasdaq: GENZ) reported that a preliminary analysis of data from an ongoing open-label Phase 2 clinical trial of its investigational oral therapy Genz-112638 showed that the compound produced a meaningful impact on key clinical manifestations of Gaucher disease. The results highlight the potential of this compound to become an innovative treatment option for Gaucher disease.